| PRECIGEN INC. |
| USA |
| Gesundheit |
| US74017N1054 / A2PZG1 |
| I5X (Frankfurt) / PGEN (NASDAQ) |
| FRA:I5X, ETR:I5X, I5X:GR, NASDAQ:PGEN |
| - |
| https://precigen.com/ |
|
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune di..
>Volltext.. |
| 987.77 Mio. EUR |
| 968.2 Mio. EUR |
| 5.44 Mio. EUR |
| -90.43 Mio. EUR |
| -212.71 Mio. EUR |
| -1.21 EUR |
| 84.61 Mio. EUR |
| 12.34 Mio. EUR |
| -62.57 Mio. EUR |
| 3.78 |
| 51.05% |
| -67.83% |
| - |
| - |
| - |
| - |
| PRECIGEN |
| 25.03.26 |
|